Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
Stock Information for Tonix Pharmaceuticals Holding Corp.
Loading
Please wait while we load your information from QuoteMedia.